Lu Wang

Prof. Lu Wang


Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 June 2020 in Nature Communications
Verified
Journal Article
Open access
PDF file
KHKuan Hu
Kuan Hu
LXLin Xie
Lin Xie
YZYiding Zhang
Yiding Zhang
MHMasayuki Hanyu
Masayuki Hanyu
ZYZhimin Yang
Zhimin Yang
MZMing-Rong Zhang
Ming-Rong Zhang
The use of photothermal agents (PTAs) in cancer photothermal therapy (PTT) has shown promising results in clinical studies. The rapid degradation of PTAs may address safety concerns but usually limits the photothermal stability required for efficacious treatment. Conversely, PTAs with high photothermal stability usually degrade slowly. The solutions that address the balance between the high photothermal stability and rapid degradation of PTAs are rare. Here, we report that the inherent Cu2+-capturing ability of black phosphorus (BP) can accelerate the degradation of BP, while also enhancing photothermal stability. The incorporation of Cu2+into BP@Cu nanostructures further enables chemodynamic therapy (CDT)-enhanced PTT. Moreover, by employing64Cu2+, positron emission tomography (PET) imaging can be achieved for in vivo real-time and quantitative tracking. Therefore, our study not only introduces an “ideal” PTA that bypasses the limitations of PTAs, but also provides the proof-of-concept application of BP-based materials in PET-guided, CDT-enhanced combination cancer therapy.

1 February 2021 in Acta Pharmaceutica Sinica B
Verified
Journal Article
Open access
LZLingling Zhang
Lingling Zhang
Kuan HuKuan Hu
Kuan Hu
TSTuo Shao
Tuo Shao
LHLu Hou
Lu Hou
SZShaojuan Zhang
Shaojuan Zhang
SLSteven H. Liang
Steven H. Liang
The 18 kDa translocator protein (TSPO), previously known as the peripheral benzodiazepine receptor, is predominately localized to the outer mitochondrial membrane in steroidogenic cells. Brain TSPO expression is relatively low under physiological conditions, but is upregulated in response to glial cell activation. As the primary index of neuroinflammation, TSPO is implicated in the pathogenesis and progression of numerous neuropsychiatric disorders and neurodegenerative diseases, including Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), Parkinson's disease (PD), multiple sclerosis (MS), major depressive disorder (MDD) and obsessive compulsive disorder (OCD). In this context, numerous TSPO-targeted positron emission tomography (PET) tracers have been developed. Among them, several radioligands have advanced to clinical research studies. In this review, we will overview the recent development of TSPO PET tracers, focusing on the radioligand design, radioisotope labeling, pharmacokinetics, and PET imaging evaluation. Additionally, we will consider current limitations, as well as translational potential for future application of TSPO radiopharmaceuticals. This review aims to not only present the challenges in current TSPO PET imaging, but to also provide a new perspective on TSPO targeted PET tracer discovery efforts. Addressing these challenges will facilitate the translation of TSPO in clinical studies of neuroinflammation associated with central nervous system diseases.

11 June 2020 in ACS Catalysis
Verified
Journal Article
Closed access
LWLu Wang
Lu Wang
TWTing Wang
Ting Wang
GCGui-Juan Cheng
Gui-Juan Cheng
XLXiaobao Li
Xiaobao Li
JWJun-Jie Wei
Jun-Jie Wei
CZChao Zheng
Chao Zheng

30 December 2020 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
LHLu Hou
Lu Hou
JRJian Rong
Jian Rong
AHAhmed Haider
Ahmed Haider
DODaisuke Ogasawara
Daisuke Ogasawara
CVCassis Varlow
Cassis Varlow
SLSteven H. Liang
Steven H. Liang

17 March 2020 in Chemical Communications
Verified
Journal Article
Closed access
PDF file
ZXZhiwei Xiao
Zhiwei Xiao
LWLu Wang
Lu Wang
JWJunjie Wei
Junjie Wei
CRChongzhao Ran
Chongzhao Ran
SLSteven H. Liang
Steven H. Liang
CZChao Zheng
Chao Zheng
A novel method has been established for the construction of C–S bonds using redox-active esters with disulfides in the presence of Ru-photoredox catalyst.

5 October 2022 in Science Translational Medicine
Verified
Journal Article
Closed access
Achi HaiderAchi Haider
Achi Haider
CZChunyu Zhao
Chunyu Zhao
LWLu Wang
Lu Wang
ZXZhiwei Xiao
Zhiwei Xiao
JRJian Rong
Jian Rong
SLSteven H. Liang
Steven H. Liang
Alterations in brain cholesterol homeostasis have been broadly implicated in neurological disorders. Notwithstanding the complexity by which cholesterol biology is governed in the mammalian brain, excess neuronal cholesterol is primarily eliminated by metabolic clearance via cytochrome P450 46A1 (CYP46A1). No methods are currently available for visualizing cholesterol metabolism in the living human brain; therefore, a noninvasive technology that quantitatively measures the extent of brain cholesterol metabolism via CYP46A1 could broadly affect disease diagnosis and treatment options using targeted therapies. Here, we describe the development and testing of a CYP46A1-targeted positron emission tomography (PET) tracer, 18 F-CHL-2205 ( 18 F-Cholestify). Our data show that PET imaging readouts correlate with CYP46A1 protein expression and with the extent to which cholesterol is metabolized in the brain, as assessed by cross-species postmortem analyses of specimens from rodents, nonhuman primates, and humans. Proof of concept of in vivo efficacy is provided in the well-established 3xTg-AD murine model of Alzheimer’s disease (AD), where we show that the probe is sensitive to differences in brain cholesterol metabolism between 3xTg-AD mice and control animals. Furthermore, our clinical observations point toward a considerably higher baseline brain cholesterol clearance via CYP46A1 in women, as compared to age-matched men. These findings illustrate the vast potential of assessing brain cholesterol metabolism using PET and establish PET as a sensitive tool for noninvasive assessment of brain cholesterol homeostasis in the clinic.